pramipexole has been researched along with pergolide in 59 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (pergolide) | Trials (pergolide) | Recent Studies (post-2010) (pergolide) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 845 | 123 | 87 |
| Protein | Taxonomy | pramipexole (IC50) | pergolide (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.379 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.385 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.264 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.2 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.111 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.385 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.064 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.41 | |
| D | Rattus norvegicus (Norway rat) | 0.0031 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0031 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.2 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.041 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 0.0603 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.679 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.041 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.041 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.513 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0031 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.014 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.379 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.2 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.385 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0031 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.385 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.385 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.385 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.385 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.385 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.385 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0054 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.385 | |
| Alpha-synuclein | Homo sapiens (human) | 7.9 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.076 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.039 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0031 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.1202 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.385 | |
| D | Bos taurus (cattle) | 0.0603 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.385 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.385 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (8.47) | 18.2507 |
| 2000's | 40 (67.80) | 29.6817 |
| 2010's | 13 (22.03) | 24.3611 |
| 2020's | 1 (1.69) | 2.80 |
| Authors | Studies |
|---|---|
| Boeckler, F; Gmeiner, P; Hübner, H; Lehmann, T; Ohnmacht, U; Utz, W | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fici, GJ; Sethy, VH; VonVoigtlander, PF; Wu, H | 1 |
| Wienkers, LC; Wynalda, MA | 1 |
| Factor, SA | 1 |
| Weiner, WJ | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Blasucci, L; Goetz, CG; Kujawa, K; Leurgans, S; Raman, R | 1 |
| Ferger, B; Mierau, J; Teismann, P | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Hanna, PA; Jankovic, J; Ondo, WG; Ratkos, L | 1 |
| Jankovic, J; Le, WD | 1 |
| Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, S; Moramarco, A; Palagano, G; Zenzola, A | 1 |
| Gekht, AB | 1 |
| Clarke, CE; Guttman, M | 1 |
| Bain, PG; Findley, LJ; Jeffs, JA; Navan, P; Pearce, RK | 2 |
| Bergmans, P; Booij, J; Stoof, JC; van Royen, EA; Winogrodzka, A; Wolters, EC | 1 |
| MacMahon, DG | 1 |
| Bankowski, BJ; Zacur, HA | 1 |
| Bares, M; Dostál, V; Ehler, E; Fanfrdlová, Z; Fiedler, J; Klajblová, H; Kulist'ák, P; Rektor, I; Rektorová, I; Ressner, P; Svátová, J; Urbánek, K; Velísková, J | 1 |
| Driver-Dunckley, E; Samanta, J; Stacy, M | 1 |
| Lang, AE; Razmy, A; Shapiro, CM | 1 |
| Chigir', IP; Fedorova, NV; Krivonos, OV | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Bain, PG; Findley, LJ; Navan, P; Pearce, RK; Undy, MB | 1 |
| Boggie, DT; Chan, H; Delattre, ML; Morreale, AP; Plowman, BK; Schaefer, MG | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Gauthier, P; Jankovic, J; Manian, P; Tintner, R | 1 |
| Morgan, JC; Sethi, KD; Sharma, P | 1 |
| Duda, JE; Goveas, J; Moberg, PJ; Morales, KH; Potenza, MN; Siderowf, AD; Stern, MB; Weintraub, D | 1 |
| Fuhrmann, JT; Junghanns, S; Koch, R; Oelwein, C; Reichmann, H; Simonis, G; Storch, A; Strasser, RH | 1 |
| Dewey, RB; O'Suilleabhain, PE; Reimold, SC | 1 |
| de Freitas, GR; Fontenelle, LF; Garcia, RF; Mendlowicz, MV; Nazar, BP; Ordacgi, L; Rosso, AL | 1 |
| Bianchi, I; Bonini, SA; Ferrari-Toninelli, G; Memo, M; Olivari, L; Uberti, D | 1 |
| Senol, MG; Togrol, RE | 1 |
| Daida, H; Hatano, T; Hattori, N; Iwama, Y; Komine-Kobayashi, M; Mizuno, Y; Mochizuki, H; Nakayama, T; Sakai, M; Urabe, T; Yamashiro, K | 1 |
| Dupuis, M; Evrard, F; Jacquerye, P; Muller, T | 1 |
| Bares, M; Krajcovicová, L; Rektor, I; Rektorová, I | 1 |
| Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C | 1 |
| Andersohn, F; Garbe, E | 1 |
| Nijssen, PC; Weber, WE | 1 |
| Fujioka, S; Iwamoto, K; Kawamura, M; Nakajima, M; Ohno, H | 1 |
| Cannas, A; Floris, G; Marrosu, F; Marrosu, MG; Piga, M; Serra, A; Solla, P; Tacconi, P | 1 |
| Caltagirone, C; Carlesimo, GA; Costa, A; Dell'Agnello, G; Peppe, A | 1 |
| Allen, RP; Earley, CJ; Senerth, J; Silver, N | 1 |
| Arai, M | 1 |
| Hornyak, M; Kohnen, R; Kriston, L; Riemann, D; Scholz, H; Trenkwalder, C | 1 |
| Allen, RP; Ball, E; Calloway, MO; Higbie, RL; Lee, MR; Manjunath, R; Nisbet, PA; Ondo, WG | 1 |
| Adam, JJ; Duits, A; Scholtissen, B; van Houdt, H; Visser-Vandewalle, V; Winogrodzka, A | 1 |
| Aurora, RN; Bista, SR; Casey, KR; Kristo, DA; Lamm, CI; Rosenberg, RS; Rowley, JA; Tracy, SL; Zak, RS | 1 |
| Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Dong, J; Liu, J; Su, Y; Sun, S; Wang, L; Yan, P | 1 |
| Hiratochi, M; Hoyano, Y; Kaidoh, K; Kikuchi, S; Oana, F; Onozuka, H; Shibata, N; Suzuki, T; Takehana, Y; Tanaka, N; Tsuchioka, A | 1 |
| Gille, G; Moldzio, R; Radad, K; Rausch, WD; Reichelt, D; Reichmann, H | 1 |
| Chen, F; Chen, X; Wen, S; Zhang, Q; Zhou, C | 1 |
16 review(s) available for pramipexole and pergolide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dopamine agonists.
Topics: Apomorphine; Benzothiazoles; Bromocriptine; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Receptors, Dopamine; Thiazoles; Treatment Outcome | 1999 |
The initial treatment of Parkinson's disease should begin with levodopa.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Drug Therapy, Combination; Essential Tremor; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine; Thiazoles; Time Factors | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Bromocriptine; Cell Culture Techniques; Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Models, Animal; Neuroprotective Agents; Parkinson Disease; Pergolide; Pramipexole; Substantia Nigra; Thiazoles | 2001 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors | 2002 |
Dopamine agonist monotherapy in Parkinson's disease.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
Dopamine agonist therapy for hyperprolactinemia.
Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles | 2003 |
Sleep attacks in patients receiving dopamine-receptor agonists.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Narcolepsy; Parkinson Disease; Pergolide; Pramipexole; Restless Legs Syndrome; Thiazoles | 2005 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.
Topics: Animals; Benzothiazoles; Dementia; Dopamine Agonists; Humans; Neuroprotective Agents; Pergolide; Pramipexole | 2007 |
Dopamine agonists for restless legs syndrome.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Levodopa; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Severity of Illness Index | 2011 |
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.
Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evidence-Based Medicine; gamma-Aminobutyric Acid; Humans; Indoles; Levodopa; Nocturnal Myoclonus Syndrome; Pergolide; Peripheral Nervous System Diseases; Pramipexole; Restless Legs Syndrome; Sleep Medicine Specialty; United States; Venous Insufficiency | 2012 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis.
Topics: Antidepressive Agents, Tricyclic; Benzothiazoles; Depression; Humans; Odds Ratio; Parkinson Disease; Pergolide; Pramipexole; Quality of Life; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2013 |
Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Pergolide; Pramipexole | 2023 |
10 trial(s) available for pramipexole and pergolide
| Article | Year |
|---|---|
Switching from pergolide to pramipexole in patients with Parkinson's disease.
Topics: Accidental Falls; Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Edema; Female; Hallucinations; Humans; Male; Middle Aged; Nausea; Parkinson Disease; Pergolide; Pramipexole; Prospective Studies; Receptors, Dopamine; Sweating; Thiazoles; Treatment Outcome | 2001 |
Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Surveys and Questionnaires; Thiazoles; Tremor | 2003 |
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pergolide; Placebos; Pramipexole; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome | 2003 |
Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
Topics: Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Thiazoles; Tremor | 2003 |
[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].
Topics: Activities of Daily Living; Benzophenones; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Pergolide; Pramipexole; Quality of Life; Thiazoles; Tolcapone; Treatment Outcome | 2004 |
A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Thiazoles; Tremor | 2005 |
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Hypertrophy, Left Ventricular; Indoles; Male; Middle Aged; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Tricuspid Valve Insufficiency | 2007 |
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Humans; Japan; Outcome Assessment, Health Care; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
Topics: Attention; Benzothiazoles; Cognition; Dopamine Agonists; Female; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pergolide; Pramipexole; Reaction Time; Severity of Illness Index; Task Performance and Analysis | 2009 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
33 other study(ies) available for pramipexole and pergolide
| Article | Year |
|---|---|
CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists.
Topics: Animals; Binding Sites; Cattle; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Humans; Indolizines; Models, Molecular; Molecular Conformation; Quantitative Structure-Activity Relationship; Radioligand Assay; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereoisomerism | 2005 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
D1 dopamine receptor activity of anti-parkinsonian drugs.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Benzothiazoles; Bromocriptine; Cells, Cultured; Cerebellum; Clozapine; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiazoles | 1997 |
Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen.
Topics: Benzothiazoles; Bromocriptine; Cytochrome P-450 Enzyme Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Humans; Indoles; Pergolide; Pramipexole; Thiazoles | 1997 |
Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Drug Administration Schedule; Female; Humans; Hypotension, Orthostatic; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Thiazoles | 2000 |
The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study.
Topics: Adrenergic Agents; Animals; Benzothiazoles; Corpus Striatum; Dopamine; Dopamine Agonists; Hydroxybenzoates; Hydroxyl Radical; Male; Microdialysis; Oxidopamine; Pergolide; Pramipexole; Rats; Rats, Wistar; Thiazoles | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
Topics: Age of Onset; Aged; Aging; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Ergolines; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome | 2001 |
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Caudate Nucleus; Cocaine; Corpus Striatum; Disease Progression; Female; Humans; Male; Nerve Degeneration; Parkinson Disease; Pergolide; Pramipexole; Putamen; Radiopharmaceuticals; Receptors, Dopamine D2; Reproducibility of Results; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2003 |
The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
Topics: Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Thiazoles | 2003 |
Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Female; Gambling; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Recurrence; Retrospective Studies; Suicide; Thiazoles | 2003 |
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Topics: Aged; Benzothiazoles; Bromocriptine; Disorders of Excessive Somnolence; Dopamine Agonists; Dose-Response Relationship, Drug; Ergot Alkaloids; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Polysomnography; Pramipexole; Prospective Studies; Sleep; Thiazoles; Wakefulness | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Drug Administration Schedule; Humans; Lung; Male; Molecular Structure; Parkinson Disease; Pergolide; Pleura; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Thiazoles; Tomography, X-Ray Computed | 2005 |
Hiccups associated with dopamine agonists in Parkinson disease.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Hiccup; Humans; Male; Parkinson Disease; Pergolide; Pramipexole; Thiazoles | 2006 |
Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Follow-Up Studies; Gambling; Humans; Indoles; Logistic Models; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Risk Factors; Sexual Behavior; Sexual Dysfunction, Physiological; Thiazoles | 2006 |
Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Case-Control Studies; Echocardiography; Female; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2007 |
Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Parkinsonian Disorders; Pergolide; Pramipexole; Recurrence | 2007 |
Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Topics: Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Parkinson Disease; Patient Selection; Pergolide; Pramipexole; Research Design; Sex Factors | 2007 |
The frequency of cardiac valvular regurgitation in Parkinson's disease.
Topics: Aged; Aortic Valve Insufficiency; Azepines; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Prevalence | 2008 |
[Isolated pulmonary hypertension and pergolide].
Topics: Antiparkinson Agents; Benserazide; Benzothiazoles; Blood Pressure; Catechols; Dyspnea; Echocardiography; Humans; Hypertension, Pulmonary; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease, Postencephalitic; Pergolide; Pramipexole | 2008 |
Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Echocardiography; Female; Heart Valve Diseases; Heart Valves; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2008 |
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors | 2009 |
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States | 2009 |
[Impulse control disorder induced by the use of dopamine agonists].
Topics: Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pergolide; Pramipexole; Restless Legs Syndrome; Risk Factors | 2009 |
Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Benzothiazoles; Brain; Carbidopa; Dopamine Agents; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Tomography, Emission-Computed, Single-Photon; Tropanes | 2009 |
A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
Topics: Analgesics, Opioid; Benzothiazoles; Chronic Disease; Dopamine Agonists; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Methadone; Pergolide; Pramipexole; Restless Legs Syndrome; Retrospective Studies; Treatment Outcome | 2011 |
Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
Topics: Aged; Arginine Vasopressin; Benzothiazoles; Carbidopa; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2011 |
Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.
Topics: Adult; Aged; Benzothiazoles; Cross-Sectional Studies; Dopamine Agonists; Female; Health Surveys; Humans; Indoles; Levodopa; Male; Middle Aged; Outpatients; Patient Satisfaction; Pergolide; Pramipexole; Restless Legs Syndrome; Risk Factors; Treatment Failure | 2011 |
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.
Topics: Aged; Benserazide; Benzothiazoles; Carbidopa; Cues; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Psychomotor Performance; Reaction Time; Subthalamic Nucleus | 2011 |
Function and expression differences between ergot and non-ergot dopamine D2 agonists on heart valve interstitial cells.
Topics: Animals; Benzothiazoles; Cell Proliferation; Cells, Cultured; Dopamine Agonists; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation; Mitral Valve; Oligonucleotide Array Sequence Analysis; Pergolide; Pramipexole; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Receptor, Serotonin, 5-HT2B; Receptors, Dopamine D2; Reproducibility of Results; RNA, Messenger; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Signal Transduction | 2014 |
Comparable Neuroprotective Effects of Pergolide and Pramipexole on Ferrous Sulfate-Induced Dopaminergic Cell Death in Cell Culture.
Topics: Animals; Benzothiazoles; Cell Death; Cycloheximide; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Interactions; Embryo, Mammalian; Ferrous Compounds; Glutathione; L-Lactate Dehydrogenase; Mesencephalon; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Pergolide; Pramipexole; Protein Synthesis Inhibitors; Statistics, Nonparametric | 2016 |